[HTML][HTML] Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a …
P Saunders, V Tsipouri, GJ Keir, D Ashby, MD Flather… - Trials, 2017 - Springer
Background Interstitial lung disease (ILD) frequently complicates systemic autoimmune
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
[PDF][PDF] Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a …
P Saunders, V Tsipouri, GJ Keir, D Ashby, MD Flather… - 2017 - core.ac.uk
Background: Interstitial lung disease (ILD) frequently complicates systemic autoimmune
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised …
P Saunders, V Tsipouri, GJ Keir, D Ashby, MD Flather… - 2017 - pubmed.ncbi.nlm.nih.gov
Background Interstitial lung disease (ILD) frequently complicates systemic autoimmune
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
[PDF][PDF] Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a …
P Saunders, V Tsipouri, GJ Keir, D Ashby, MD Flather… - 2017 - scienceopen.com
Background: Interstitial lung disease (ILD) frequently complicates systemic autoimmune
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised …
P Saunders, V Tsipouri, GJ Keir, D Ashby, MD Flather… - Trials, 2017 - discovery.ucl.ac.uk
BACKGROUND: Interstitial lung disease (ILD) frequently complicates systemic autoimmune
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
[PDF][PDF] Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a …
P Saunders, V Tsipouri, GJ Keir, D Ashby, MD Flather… - 2017 - research-portal.uea.ac.uk
Background: Interstitial lung disease (ILD) frequently complicates systemic autoimmune
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised …
P Saunders, V Tsipouri, GJ Keir, D Ashby, MD Flather… - Trials, 2017 - search.proquest.com
Background Interstitial lung disease (ILD) frequently complicates systemic autoimmune
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised …
P Saunders, V Tsipouri, GJ Keir, D Ashby, MD Flather… - Trials, 2017 - go.gale.com
Background Interstitial lung disease (ILD) frequently complicates systemic autoimmune
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised …
P Saunders, V Tsipouri, GJ Keir, D Ashby, MD Flather… - Trials, 2017 - ueaeprints.uea.ac.uk
Background: Interstitial lung disease (ILD) frequently complicates systemic autoimmune
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …
[HTML][HTML] Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a …
P Saunders, V Tsipouri, GJ Keir, D Ashby… - …, 2017 - trialsjournal.biomedcentral.com
Interstitial lung disease (ILD) frequently complicates systemic autoimmune disorders
resulting in considerable morbidity and mortality. The connective tissue diseases (CTDs) …
resulting in considerable morbidity and mortality. The connective tissue diseases (CTDs) …